A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-11-16
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 95); relationship: N
moderate
assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-04-06 (study day 126); relationship: N
severe
assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-08 (study day 189); relationship: N
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-11-19 (study day 353); relationship: N
Data queries
No data queries.